This brand name is authorized in the following countries: Austria Australia Estonia Spain Finland Ireland Lithuania New Zealand Poland United Kingdom
The drug BUVIDAL contains one active pharmaceutical ingredient (API):
Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the μ (mu) and κ (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the μ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence.
Below package inserts are available for further reading:
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This drug has been assigned below unique identifiers within the countries it is being marketed:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.